Based on the results of more than 200 randomized trials, HbA1c is not a valid surrogate marker for all-cause mortality in people with type 2 diabetes (Acta Diabetologica)
Diabetes News
Tag: mortality
Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes
CVD and LLA conferred a similar burden regarding mortality in type 1 diabetes population. Our findings encourage a careful consideration of people with type 1 diabetes and LLA as usually recommended for those with CVD, in terms of management of risk factors, treatments and prevention (Cardiovascular Diabetology)
Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts
This is the first multicountry analysis of six large contemporary population-based studies, and shows that all-cause mortality in people with type 1 diabetes has declined in recent years in most studied populations. However, excess mortality relative to the population without diabetes remains high in people with type 1 diabetes (Diabetologia)
Mortality Rate Associated with Diabetes: Outcomes From a General Practice Level Analysis in England Using the Royal College of General Practitioners (RCGP) Database Indicate Stability Over a 15 Year Period
There remains a wide variation in mortality rate of people with diabetes between general practices in UK. The mortality rate and life years lost for people with diabetes vs non-diabetes individuals have remained stable in recent years, while mortality rates for the general population have fallen (Diabetes Therapy)
Association between dysglycemia and mortality by diabetes status and risk factors of dysglycemia in critically ill patients: a retrospective study
The identified factors for dysglycemia could be used for risk assessment in glucose management requirement in critically ill patients, which may improve clinical outcomes (Acta Diabetologica)
Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients
SHR was the most consistent independent predictor of 1-year all-cause mortality in both diabetic and non-diabetic STEMI, whereas glucose was the best predictor in NSTEMI patients (Cardiovascular Diabetology)
Completion of annual diabetes care processes and mortality: A cohort study using the National Diabetes Audit for England and Wales
People with diabetes who have fewer routine care processes have higher mortality (Diabetes, Obesity and Metabolism)
Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
The initiation of SGLT-2i as compared with other glucose-lowering drugs in routine clinical practice is associated with decreased risk of heart failure, all-cause death, myocardial infarction and stroke (Cardiovascular Diabetology)
All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease
Our data show that two well-established prediction models of all-cause mortality in type 2 diabetes can also be successfully applied in the early stage of the disease, thus becoming powerful tools for educated and timely prevention strategies for high-risk patients (Acta Diabetologica)
Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records
The decline in vascular death rates has been accompanied by a diversification of causes in individuals with diagnosed diabetes and a transition from vascular diseases to cancers as the leading contributor to diabetes-related death. Clinical and preventative approaches must reflect this trend to reduce the excess mortality risk in individuals with diabetes (Lancet Diabetes & Endocrinology)
Potential Unrealized Mortality Benefit of GLP‐1 Receptor Agonists and SGLT2 Inhibitors
This analysis indicates unrealized opportunities to reduce mortality in selected Veterans with T2D and CAD via increased use of GLP‐1RA and SGLT2i (Diabetes, Obesity and Metabolism)
Organisation of primary diabetes care in people with type 2 diabetes in relation to all-cause mortality: a nationwide register-based cohort study
This nationwide register-based cohort study suggests that the number of WTE GPs devoted to diabetes care have an impact on the risk of early death in people with T2DM (Diabetes Research and Clinical Practice)
Pain in Patients With Type 2 Diabetes-Related Polyneuropathy Is Associated With Vascular Events and Mortality
Our study found a significant association between pain in DPN and an increased risk of vascular events and mortality (Journal of Clinical Endocrinology & Metabolism)
Type 1 and Type 2 diabetes and COVID-19 related mortality in England: a cohort study in people with diabetes
Deaths in people with diabetes in England have more than doubled during the COVID-19 epidemic. Hyperglycaemia and obesity in both Type 1 and Type 2 diabetes were independently associated with increased COVID-19 mortality. Risk factor control could diminish the impact of COVID-19 in diabetes (NHS England)
Type 1 and Type 2 diabetes and COVID-19 related mortality in England: a whole population study
This nationwide analysis in England demonstrates that all types of diabetes are independently associated with a significant increased risk of in-hospital death with COVID-19 (NHS England)
Socio‐economic status and mortality in people with type 1 diabetes in Scotland 2006–2015: a retrospective cohort study
Socio‐economic deprivation was associated with a steeper mortality gradient in people with type 1 diabetes than in the population without type 1 diabetes in Scotland. Age‐standardized mortality has decreased over time but socio‐economic inequalities may be increasing. (Diabetic Medicine)
Relationship Between Body Mass Index, Antidiabetic Agents, and Midterm Mortality in Patients With Both Type 2 Diabetes Mellitus and Acute Coronary Syndrome
In patients with type 2 diabetes mellitus and acute coronary syndrome, the relationship between body mass index and mortality rate is U‐shaped, with class I obesity representing the nadir and normal weight the peak. The protective effect of obesity disappeared in patients treated with insulin (JAHA)
The All-Cause Mortality and a Screening Tool to Determine High-Risk Patients among Prevalent Type 2 Diabetes Mellitus Patients
The model has moderate accuracy; the prognostic model can be used as a screening tool to classify T2DM patients who are at higher risk for mortality within five years (Journal of Diabetes Research)
Multiple risk factor control, mortality and cardiovascular events in type 2 diabetes and chronic kidney disease: a population-based cohort study
Multiple risk factor control (MRFC) may lower the increased risks for mortality and cardiovascular events in people with diabetes and CKD (BMJ Open)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo (Diabetes Care)
Glycosmedia is also available as an App: